IN2014MN01547A - - Google Patents

Info

Publication number
IN2014MN01547A
IN2014MN01547A IN1547MUN2014A IN2014MN01547A IN 2014MN01547 A IN2014MN01547 A IN 2014MN01547A IN 1547MUN2014 A IN1547MUN2014 A IN 1547MUN2014A IN 2014MN01547 A IN2014MN01547 A IN 2014MN01547A
Authority
IN
India
Prior art keywords
compounds
disclosed
methods
agents
host
Prior art date
Application number
Other languages
English (en)
Inventor
Vidya Ramdas
Advait Arun Joshi
Moloy Manoj Banerjee
Amit Kumar Das
Deepak Sahebrao Walke
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN1547MUN2014 priority Critical patent/IN2014MN01547A/en
Publication of IN2014MN01547A publication Critical patent/IN2014MN01547A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN1547MUN2014 2012-02-10 2013-02-08 IN2014MN01547A (cg-RX-API-DMAC7.html)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1547MUN2014 IN2014MN01547A (cg-RX-API-DMAC7.html) 2012-02-10 2013-02-08

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN147KO2012 2012-02-10
IN1017KO2012 2012-09-04
PCT/IB2013/051062 WO2013118097A1 (en) 2012-02-10 2013-02-08 Antiviral compounds with a dibenzooxaheterocycle moiety
IN1547MUN2014 IN2014MN01547A (cg-RX-API-DMAC7.html) 2012-02-10 2013-02-08

Publications (1)

Publication Number Publication Date
IN2014MN01547A true IN2014MN01547A (cg-RX-API-DMAC7.html) 2015-05-08

Family

ID=54259033

Family Applications (2)

Application Number Title Priority Date Filing Date
IN1547MUN2014 IN2014MN01547A (cg-RX-API-DMAC7.html) 2012-02-10 2013-02-08
IN1548MUN2014 IN2014MN01548A (cg-RX-API-DMAC7.html) 2012-02-10 2013-02-09

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN1548MUN2014 IN2014MN01548A (cg-RX-API-DMAC7.html) 2012-02-10 2013-02-09

Country Status (14)

Country Link
US (2) US9073943B2 (cg-RX-API-DMAC7.html)
EP (2) EP2812326A1 (cg-RX-API-DMAC7.html)
JP (1) JP6034883B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140129034A (cg-RX-API-DMAC7.html)
CN (1) CN104136433B (cg-RX-API-DMAC7.html)
AU (2) AU2013217224B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014019584A8 (cg-RX-API-DMAC7.html)
CA (2) CA2862755A1 (cg-RX-API-DMAC7.html)
IN (2) IN2014MN01547A (cg-RX-API-DMAC7.html)
MX (1) MX2014009546A (cg-RX-API-DMAC7.html)
NZ (2) NZ628515A (cg-RX-API-DMAC7.html)
SG (2) SG11201404475TA (cg-RX-API-DMAC7.html)
WO (2) WO2013118097A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201405490B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102863428B (zh) 2011-07-09 2014-12-24 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的螺环化合物
NZ628515A (en) 2012-02-10 2016-06-24 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR102794564B1 (ko) * 2016-04-08 2025-04-15 듀폰스페셜티머터리얼스코리아 유한회사 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자
US11208527B2 (en) 2016-04-15 2021-12-28 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
UY38705A (es) * 2019-05-23 2020-12-31 Irbm S P A Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
CN114605310B (zh) * 2022-04-09 2024-05-07 都创(上海)医药科技股份有限公司 一种氮杂五元环并三元环羧酸酯衍生物及其盐的合成方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO2004014313A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
JPWO2005012284A1 (ja) 2003-07-31 2007-09-27 大正製薬株式会社 4,5−ジヒドロナフト[1,2−b]チオフェン誘導体
DK2243766T3 (en) 2003-09-19 2015-10-12 Janssen Pharmaceutica Nv 4 - ((phenoxyalkyl) thio) -phenoxyeddikesyrer for use in the treatment of PPAR delta mediated conditions
EP1682528B1 (en) 2003-11-07 2007-09-12 F. Hoffmann-La Roche Ag BENZO [b][1,4] DIOXEPINE DERIVATIVES
GB0421908D0 (en) 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
GB0501964D0 (en) 2005-01-31 2005-03-09 Arrow Therapeutics Ltd Chemical compounds
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
DK1940786T3 (da) 2005-09-16 2010-11-08 Arrow Therapeutics Ltd Biphenylderivater og deres anvendelse ved behandling af hepatitis C
EP1971597A2 (en) 2005-12-12 2008-09-24 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
KR20080075909A (ko) 2005-12-12 2008-08-19 제네랩스 테크놀로지스, 인코포레이티드 N-(6-원 방향족 환)-아미도 항-바이러스 화합물
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA200970375A1 (ru) 2006-10-13 2009-10-30 Президио Фармасьютикалз, Инк. Соединения и способы лечения вируса гепатита с
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100055071A1 (en) 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
WO2008064218A2 (en) 2006-11-21 2008-05-29 Smithkline Beecham Corporation Amido anti-viral compounds
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200906826A (en) 2007-06-12 2009-02-16 Genelabs Tech Inc Anti-viral inhibitors and methods of use
JP5395068B2 (ja) 2007-06-29 2014-01-22 ギリアード サイエンシーズ, インコーポレイテッド トール様受容体7の調節物質としてのプリン誘導体およびその使用
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
WO2009034390A1 (en) 2007-09-14 2009-03-19 Arrow Therapeutics Limited Heterocyclic derivatives and their use in treating hepatitis c
MX2010003916A (es) 2007-10-10 2010-05-05 Novartis Ag Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih).
MX2010008699A (es) 2008-02-12 2010-08-30 Bristol Myers Squibb Co Derivados heterociclicos como inhibidores de virus de la hepatitis c.
BRPI0822335A2 (pt) 2008-02-12 2019-09-24 Bristol-Myers Squibb Company inibidores do vírus da hepatite c
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102007122B (zh) 2008-02-13 2013-09-04 百时美施贵宝公司 作为丙型肝炎病毒抑制剂的咪唑基联苯基咪唑
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AP3076A (en) 2008-04-23 2014-12-31 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20110217265A1 (en) 2008-09-23 2011-09-08 Glenn Jeffrey S Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
CA2750577A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CN102348713B (zh) 2009-02-10 2015-12-02 吉里德科学公司 用于抗病毒治疗的carba-核苷类似物
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
MY169311A (en) 2009-03-27 2019-03-21 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20180028070A (ko) 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
AU2010280711A1 (en) 2009-08-07 2012-02-09 Janssen Sciences Ireland Uc Phenyl ethynyl derivatives as hepatitis C virus inhibitors
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
EP2475254A4 (en) 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
CA2784036A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AR080433A1 (es) 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
EP2542074A4 (en) 2010-03-04 2014-05-14 Enanta Pharm Inc PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
KR20130008040A (ko) 2010-03-09 2013-01-21 머크 샤프 앤드 돔 코포레이션 융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011151651A1 (en) 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
WO2011151652A1 (en) 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
AR081848A1 (es) 2010-06-09 2012-10-24 Presidio Pharmaceuticals Inc Inhibidores de la proteina ns5a del vhc
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2601188B1 (en) 2010-08-04 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA2808291A1 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
CA2812699A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BR112013007696A2 (pt) 2010-09-29 2019-09-24 Merck Sharp & Dohme composto, composição farmacêutica, usos do referido composto e da referida composição
EP2621932A4 (en) 2010-09-29 2014-03-26 Merck Sharp & Dohme TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
AU2011328980B2 (en) 2010-11-17 2015-07-30 Gilead Sciences, Inc. Antiviral compounds
NZ628515A (en) 2012-02-10 2016-06-24 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety

Also Published As

Publication number Publication date
JP6034883B2 (ja) 2016-11-30
AU2013217229B2 (en) 2017-03-02
NZ628515A (en) 2016-06-24
US9073942B2 (en) 2015-07-07
US9073943B2 (en) 2015-07-07
WO2013118102A1 (en) 2013-08-15
AU2013217224A1 (en) 2014-08-21
US20150010505A1 (en) 2015-01-08
SG11201404365SA (en) 2014-10-30
ZA201405490B (en) 2015-10-28
NZ628445A (en) 2016-05-27
WO2013118097A1 (en) 2013-08-15
MX2014009546A (es) 2015-10-29
CA2862755A1 (en) 2013-08-15
AU2013217224B2 (en) 2017-04-06
AU2013217229A1 (en) 2014-08-21
SG11201404475TA (en) 2014-08-28
CN104136433A (zh) 2014-11-05
CA2862330A1 (en) 2013-08-15
IN2014MN01548A (cg-RX-API-DMAC7.html) 2015-05-08
EP2812327A1 (en) 2014-12-17
KR20140129034A (ko) 2014-11-06
EP2812326A1 (en) 2014-12-17
CN104136433B (zh) 2016-05-04
BR112014019584A2 (cg-RX-API-DMAC7.html) 2017-06-20
JP2015510512A (ja) 2015-04-09
US20150010504A1 (en) 2015-01-08
BR112014019584A8 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
IN2014MN01547A (cg-RX-API-DMAC7.html)
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703064A (en) Inhibitors of hepatitis c virus
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2020003055A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
NZ748966A (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
MX2012000959A (es) Inhibidores de los virus flaviviridae.
TN2012000358A1 (en) Hepatitis c virus inhibitors
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
IN2012DN01855A (cg-RX-API-DMAC7.html)
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
WO2013059278A3 (en) Hepatitis c virus inhibitors
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
HK1198387A1 (zh) 用作黃病毒科病毒抑制物之噻吩-2-羧酸衍生物